Dynavax Announces the Appointment of Two New Board Members
July 21 2020 - 4:10PM
Dynavax Technologies Corporation (Nasdaq: DVAX), a
biopharmaceutical company focused on developing and commercializing
novel vaccines, today announced the appointment of Ms. Julie
Eastland and Mr. Brent MacGregor to its Board of Directors.
“We are delighted to welcome Julie and Brent,
both highly experienced professionals within their respective
fields, to the Dynavax Board of Directors,” commented Ryan Spencer,
Chief Executive Officer of Dynavax. “I look forward to their
strategic input as Dynavax continues to build a leading vaccine
company on the foundation of HEPLISAV-B, our FDA-approved adult
hepatitis B vaccine, CpG 1018, our advanced vaccine adjuvant, and
the company’s significant expertise in vaccine development,
manufacturing and commercialization.”
Julie Eastland previously served as Chief
Financial Officer and Chief Business Officer of Rainier
Therapeutics, a private biopharmaceutical company focused in FGFR3
bladder cancer. Prior to Rainier she served as Chief Financial
Officer and Chief Business Officer of Cascadian Therapeutics, a
publicly traded company. While at Cascadian, Ms. Eastland was
instrumental in the negotiation and sale of the company to Seattle
Genetics, primarily for tucatinib, a HER2 targeted breast cancer
therapy now marketed as Tukysa. Prior to Cascadian, Ms. Eastland
served as Chief Financial Officer and Vice President of Finance and
Operations of VLST Corporation, a privately-held biotechnology
company, and held various financial and strategic management
positions at publicly traded biotechnology companies including
Dendreon and Amgen. Ms. Eastland received an M.B.A. from Edinburgh
University Management School and a B.S. in finance from Colorado
State University.
Brent MacGregor previously served as Senior
Vice-President, Global Commercial Operations at Seqirus, a CSL
Limited company. At Seqirus, Mr. MacGregor led a global team
of 280 people in sales, marketing, commercial development, public
policy and business development for a portfolio of seasonal
influenza vaccines, an intra venous anti-viral product, a suite of
in-licensed vaccines and pharmaceutical products, and a pandemic
and pre-pandemic business. Prior to Seqirus, Mr. MacGregor was
President and Global Head of Novartis Influenza Vaccines, where he
led integrated global operations of its influenza portfolio,
through its acquisition by CSL Ltd. Mr. MacGregor held several
roles while at Sanofi Pasteur where he spent 17 years with his
final role as President, Sanofi Pasteur KK, Tokyo, Japan. Mr.
MacGregor received an M.B.A. from Northwestern University, Kellogg
School of Management, a Master of Arts from University of Reading,
Reading, England and a Bachelor of Arts from Carleton University,
Ottawa, Canada.
About DynavaxDynavax is a
commercial stage biopharmaceutical company developing and
commercializing novel vaccines. The Company launched its first
commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant),
Adjuvanted], in February 2018, following U.S. FDA approval for
prevention of infection caused by all known subtypes of hepatitis B
virus in adults age 18 years and older. Dynavax is also
further developing CpG 1018 as an advanced vaccine adjuvant through
research collaborations and partnerships. Current
collaborations are focused on adjuvanted vaccines for COVID-19 and
pertussis. For more information, visit www.dynavax.com and follow
the company on LinkedIn.
Dynavax ContactsNicole Arndt, Senior Manager,
Investor Relationsnarndt@dynavax.com510-665-7264
Derek Cole, President Investor Relations Advisory Solutions
derek.cole@IRadvisory.com
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Apr 2023 to Apr 2024